Physician profile
Dong Wang
NPI 1497905913
$19,423.35
in general payments reported to CMS, 2019-2025
78 companies · $4,091 in 2025
The $4,091 reported for 2025 was more than what 83% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,224 · 2020: $1,905 · 2021: $2,959 · 2022: $3,263 · 2023: $2,462 · 2024: $3,519 · 2025: $4,091.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,903 · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,902.94 |
| Education | $168.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,076.84 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Novartis Pharmaceuticals Corporation | $1,858.27 | 2019-2025 | |
| Abbvie INC. | $1,855.00 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Emd Serono, INC. | $954.74 | 2019-2025 | Mavenclad, Mavenclad |
| Teva Pharmaceuticals USA, INC. | $877.95 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Pfizer INC. | $763.49 | 2023-2025 | |
| Sk Life Science, INC. | $720.32 | 2020-2025 | |
| Lundbeck LLC | $719.29 | 2021-2025 | Vyepti, Rexulti |
| Biohaven Pharmaceuticals, INC. | $707.88 | 2020-2021 | |
| Lilly USA, LLC | $615.99 | 2019-2025 | Emgality, Amyvid, Kisunla |
| Neurocrine Biosciences, INC. | $600.63 | 2022-2025 | Ingrezza, Ongentys |
| Amgen INC. | $537.78 | 2019-2025 | Uplizna, Aimovig |
| Biohaven Pharmaceutical Holding Company Ltd. | $534.00 | 2022 | |
| Acadia Pharmaceuticals INC | $524.44 | 2019-2025 | Nuplazid, Daybue |
| Eisai INC. | $502.66 | 2020-2024 |
Show all 78 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dong Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.